期刊文献+

Ⅰ期非小细胞肺癌术前与术后血清癌胚抗原浓度变化与预后的相关性分析 被引量:4

下载PDF
导出
摘要 0引言 肺癌是人类常见的恶性肿瘤,近几十年来我们对于肺癌的认识以及对其治疗也取得了一定的进展,但非小细胞肺癌(NSCLC)的生存率并未得到明显的提高。临床上Ⅰ期NSCLC治疗预后最佳,5年生存率可达60%~80%,但即使对于完全切除的Ⅰ期NSCLC复发率仍然达25%~50%。Ⅰ期NSCLC往往无明显临床症状,因此早期诊断较为困难,而血清肿瘤标志物如CEA等在肺癌的早期诊断、疗效评估和指预后等方面起着重要的作用。
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2012年第5期586-588,共3页 Cancer Research on Prevention and Treatment
基金 南京市医学科技发展基金资助项目(QYK10170)
  • 相关文献

参考文献16

  • 1Michael C,James D,Virginia R,et al. Prognostic significance ofmicro-metastasis in non- small cell lung cancer[J]. Clin Lung Cancer,2004,5 (4) : 214-25.
  • 2Edge SB, Byrd DR, Compton CC, et al. American Joint Com- mittee on Cancer(AJCC) cancer staging manual[M]. 7th ed. Chicago & Springer, Inc, 2010, PP253-70.
  • 3Ginsberg MS. Epidemiology of lung cancer[J]. Semin Roentgenol, 2005,40(2) :83-9.
  • 4Bastarrika G,Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and posi- tron emission tomography[J]. Am J Respir Crit Care Med, 2005,171 (12) : 1378-83.
  • 5Twombly R. Lung cancer screening debate continues despite international CT study results[J]. J Nati Cancer Inst, 2007,99 (3) : 190-5.
  • 6Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 onco- protein in non-small-cell lung cancer: A favorable prognostic factor[J]. J Clin Oncol, 1995,13 (8) : 1893-903.
  • 7Pezzella F,Turley H, Kuzu I, et al. bcl-2 protein in non-small- cell lung carcinoma[J]. N Engl J Med, 1993,329 (10) : 690-4.
  • 8Polldn M, Varela G, Torres A, et al. Clinical value of p53, c- erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer[J]. Int J Cancer, 201)3,107 (5) : 781-90.
  • 9Okada M, Sakamoto T, Nishio W, et al. Characteristics and prog- nosis of patients after resection of non-small cell lung carcino- ma measuring 2 cm or less in greatest dimension[J]. Cancer, 2003,98(3) :535-41.
  • 10Okada M, Nishio W, Sakamoto T, et al. Prognostic significance of perioperative serum carcinoernbryonie antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stagel disease [J]. Ann Thorac Surg, 2004, 78 (1): 216-21.

同被引文献35

  • 1莫军扬,朱其一,庄亚强,黄平.新辅助化疗对晚期乳腺癌患者T淋巴细胞亚群免疫功能的影响[J].实用癌症杂志,2007,22(5):454-456. 被引量:6
  • 2Ginsberg MS. Epidemiology of lung eancerI-J. Semin Roent- genol, 2005,40(2) .. 83-89.
  • 3Twombly R. Lung cancer screening debate continues despite international CT study results[-J3. J Natl Cancer Inst,2007, 99(3):190-195.
  • 4Pujol JL, Grenier J, Daurs JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunora- diometric assay as a marker of lung caneerJ]. Cancer Res, 1993,53 (1) : 61-66.
  • 5Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non- small-cell lung carcinomas[J]. J Clin Oncol, 1999, 17 (7): 2086-2091.
  • 6Matsuguma H, Nakahara R, Igarashi S, et al. Pathologic stage I non-small-cell lung cancerwith high l.evels of preopera- tive serum carcinoembryonic antigen: clinicopathologic charac- teristics and prognosisEJ. J Thorac Cardiovasc Surg, 2008, 135(1) :44-49.
  • 7Li SH,Wang Z,Liu XY,et al. Gene diagnosis and prognostic significance of lymph node micrometastasis after complete resection of histologically node negative non-small cell lung eancer[-]. World J Surg, 2008,32 (8) : 1651-1656.
  • 8Steger V, Spengler W, Hetzel J, et al.Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer[J] Eur J Cardiothorac Surg,2012,41(4): 880-885.
  • 9Saha SP,Kalathiya RJ, Davenport DL, et al. Survival after Pneumoneeto- my for Stage III Non-small Cell Lung Cancer[J].Oman Med J,2014,29 (1):24-27.
  • 10Steger V, Walker T, Mustafi M, et al.Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the re- suits justify the risk?[J]. Interact Cardiovase Thorac Surg, 2012, 15(6): 948-953.

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部